Summary
65 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 42% a year over the last 3 years.
- It bought back its own shares for $333.3M in the last fiscal year, 5.8% of its market value.
- Out of every 100 USD of revenue, 14 USD is left as free cash.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against the industry (Medical - Instruments & Supplies)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.6% a year over 5 years. Over the last 3 years it grew by 6.4% a year. For the next fiscal year analysts expect revenue to grow by 2.5%. Earnings per share grew by 42% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, stretched- Yield
- 2.58%
- Paid out of profit
- 82%
- Raised in a row
- 1 year
You receive $0.08 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.